Resolutions from the Annual General Meeting of Novo Nordisk A/S

Bagsværd, Denmark, 24 March 2022 – Nowadays, Novo Nordisk A/S held its Yearly Standard Meeting.

At the Annual Typical Assembly, Helge Lund, chair of the Board of Administrators communicated: “Novo Nordisk manufactured superior progress in the past 12 months and exceeded expectations with sturdy fiscal effectiveness. We broadened our technological know-how platforms and product pipeline to bolster the foundation for very long-expression progress, while investing significantly in expanding our long term creation capability. Our long-standing aspiration of developing price for culture is extra appropriate than ever, and we carry on to provide a lot more people in need around the entire world in line with our reason of driving adjust in diabetic issues and other serious persistent illness.”

Resolutions adopted at the Yearly Basic Assembly
Economical yr 2021 and board remuneration

• The final dividend for 2021 of DKK 6.90 for just about every Novo Nordisk A or B share of DKK .20. The complete dividend for 2021 of DKK 10.40 incorporates equally the interim dividend of DKK 3.50 for every single Novo Nordisk A and B share of DKK .20 which was paid in August 2021 and the closing dividend of DKK 6.90 for every Novo Nordisk A and B share of DKK .20 to be paid out in March 2022. T

• The precise remuneration of the Board of Administrators for 2021 and the remuneration stage for 2022 ended up approved.

• The Remuneration Report 2021 was authorised (advisory vote).

Elections

• Re-election of Helge Lund as chair of the Board of Directors.

• Election of Henrik Poulsen as vice chair of the Board of Administrators.

• Re-election of Jeppe Christiansen, Laurence Debroux, Andreas Fibig, Sylvie Grégoire, Kasim Kutay and Martin Mackay as members of the Board of Administrators.

• Election of Christina Legislation as new member of the Board of Administrators.

• Re-appointment of Deloitte Statsautoriseret Revisionspartnerselskab as the Company’s auditor.

Shares and capital

• Reduction of the Company’s B share cash by cancellation of aspect of the Company’s own keeping of B shares. The Company’s B share cash is minimized by DKK 6,000,000 from DKK 354,512,800 to DKK 348,512,800. The Company’s A share cash of DKK 107,487,200 stays unchanged, whereby the Company’s share money will sum to DKK 456,000,000.

• Authorisation to the Board of Directors until eventually the Once-a-year Basic Meeting 2023 to allow for the Enterprise to repurchase possess shares of up to 10% of the share capital subject to a holding restrict of 10% of the share funds.

• Extension of the authorisation to the Board of Administrators to boost the Company’s share money for a interval of 1 year until 24 March 2024 up to nominally DKK 45,600,000.

Story proceeds

Other

• Amendments to the Remuneration Coverage relating to payment of contribution to social safety taxes imposed by overseas authorities outside the house the EU and concerning severance payment.

• Modification to the Articles or blog posts of Affiliation pertaining to removing of age restrict on candidates standing for election to the Board of Administrators.

The conference was held as a partly electronic assembly enabling shareholders to participate either in particular person or almost. The shareholders experienced been encouraged to exercise their legal rights by distributing proxies or votes by correspondence in progress of the Annual Common Assembly.

Composition of the Board of Administrators and its committees
In February 2022, Novo Nordisk staff members in Denmark elected 4 board members, Elisabeth Dahl Christensen, Liselotte Hyveled, Mette Bøjer Jensen and Thomas Rantzau for a period of time of 4 a long time adhering to the Once-a-year General Meeting 2022.

Soon after the Annual General Conference, the Board of Administrators held a board conference to appoint members of its committees.

The Board of Administrators, which includes its committees, is now composed as follows:

• Helge Lund (chair of the Board and chair of the Nomination Committee)

• Henrik Poulsen (vice chair of the Board, member of the Audit Committee and the Remuneration Committee)

• Elisabeth Dahl Christensen (worker consultant and member of the Remuneration Committee)

• Jeppe Christiansen (chair of the Remuneration Committee)

• Laurence Debroux (chair of the Audit Committee and member of the Remuneration Committee)

• Andreas Fibig (member of the Analysis & Progress Committee)

• Sylvie Grégoire (member of the Audit Committee, the Nomination Committee and the Research & Enhancement Committee)

• Liselotte Hyveled (personnel agent and member of the Investigation & Growth Committee)

• Mette Bøjer Jensen (worker agent and member of the Audit Committee)

• Kasim Kutay (member of the Nomination Committee and the Research & Improvement Committee)

• Christina Regulation (member of the Audit Committee)

• Martin Mackay (chair of the Exploration & Improvement Committee and member of the Remuneration Committee)

• Thomas Rantzau (worker representative and member of the Nomination Committee)

Novo Nordisk is a primary world-wide healthcare business, established in 1923 and headquartered in Denmark. Our reason is to push change to defeat diabetic issues and other really serious chronic diseases these kinds of as weight problems and uncommon blood and endocrine diseases. We do so by revolutionary scientific breakthroughs, growing obtain to our medicines and working to avert and ultimately cure condition. Novo Nordisk employs about 47,800 men and women in 80 international locations and marketplaces its products and solutions in around 170 nations. Novo Nordisk’s B shares are stated on Nasdaq Copenhagen (Novo-B). Its ADRs are stated on the New York Stock Trade (NVO). For extra information and facts, stop by novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.

Even more data

Organization announcement No 25 / 2022

Attachment